These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37151179)

  • 21. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments.
    Zekeridou A; Majed M; Heliopoulos I; Lennon VA
    Thorac Cancer; 2019 Apr; 10(4):1001-1004. PubMed ID: 30810271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy.
    Valencia-Sanchez C; Zekeridou A
    Front Neurol; 2021; 12():642800. PubMed ID: 33897597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-mediated diseases involving central and peripheral nervous systems.
    Leboyan A; Esselin F; Bascou AL; Duflos C; Ion I; Charif M; Castelnovo G; Carra-Dalliere C; Ayrignac X; Kerschen P; Chbicheb M; Nguyen L; Maria ATJ; Guilpain P; Carriere M; de Champfleur NM; Vincent T; Jentzer A; Labauge P; Devaux JJ; Taieb G
    Eur J Neurol; 2023 Feb; 30(2):490-500. PubMed ID: 36366904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
    J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies.
    Lucchinetti CF; Kimmel DW; Lennon VA
    Neurology; 1998 Mar; 50(3):652-7. PubMed ID: 9521251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotoxicities associated with immune checkpoint inhibitor therapy.
    Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
    J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
    Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
    Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurologic manifestations of autoimmunity with immune checkpoint inhibitors.
    McCombe JA; Sechi E; Zekeridou A
    Handb Clin Neurol; 2024; 200():449-465. PubMed ID: 38494296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study.
    Reid P; Liew DF; Akruwala R; Bass AR; Chan KK
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34526389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
    Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
    J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy.
    Kang K; Zheng K; Zhang Y
    J Immunother; 2020 Jun; 43(5):165-168. PubMed ID: 32195750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome.
    Valencia-Sanchez C; Knight AM; Hammami MB; Guo Y; Mills JR; Kryzer TJ; Piquet AL; Amin A; Heinzelmann M; Lucchinetti CF; Lennon VA; McKeon A; Pittock SJ; Dubey D
    J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):196-200. PubMed ID: 34921120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autonomic nervous system involvement in autoimmune encephalitis and paraneoplastic neurological syndromes.
    Villagrán-García M; Farina A; Campetella L; Arzalluz-Luque J; Honnorat J
    Rev Neurol (Paris); 2024; 180(1-2):107-116. PubMed ID: 38142198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer.
    Takahara Y; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Sakuma T; Nishiki K; Nakase K; Nojiri M; Kato R; Shinomiya S; Fujimoto Y; Oikawa T; Mizuno S
    Thorac Cancer; 2022 Feb; 13(4):624-630. PubMed ID: 34989146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes.
    Blaes F
    Expert Rev Neurother; 2021 Jun; 21(6):675-686. PubMed ID: 33960258
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
    Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
    Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.